NEOADJUVANT CHEMOTHERAPY FOR EPITHELIAL OVARIAN CANCER. MODERN METHODS AND PATIENTS SELECTION CRITERIA
https://doi.org/10.17749/2313-7347.2016.10.2.044-054
Abstract
Ovarian cancer is the 3rd most common cancer among women with gynecological neoplasms in Russia, at the same time, it have the highest mortality rate among malignant tumors of the female reproductive system. Because ofvague clinical picture and the lack of effective methods for early detection and screening, more than 60% of cases are diagnosed at stage III-IV, after the spread of tumor beyond the pelvis. Standard treatment for this category of patients includes debulking surgery on the first stage, followed by adjuvant chemotherapy. The main predictor of the prognosis is the residualvolume of disease after debulking surgery. Nowadays, complete resection of all macroscopic disease is considered as optimal cytoreduction. Trying to perform surgical treatment in the optimal volume dictates the need for complex, multi-component operations, accompanied by significant postoperative morbidity and mortality. In addition, in many cases, resection of all macroscopic foci of the disease is technically impossible.The use of neoadjuvant chemotherapy is designed to reduce the incidence of postoperative complications and to achieve optimal cytoreduction in the maximum number of patients.After an analysis of literature the authors could make up aconclusion that the place of neoadjuvant chemotherapy in the treatment of advanced forms of ovarian cancer is still arguable. Based on data from clinical trials, the primary debulking surgery after the diagnosis is the best treatment for this category of patients. However, among patients with markers of unresectability according to the radiologic methods, as well as patients with poor performance status, that significantly increases the risk of surgery, use of neoadjuvant chemotherapy is a reasonable method of choice.
About the Authors
A. E. Solopova
Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation
Russian Federation
docent at the Department of Radiology,
Trubetskaya, 8, str. 2, Moskva, 119991
A. A. Chashchin
Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation
Russian Federation
intern of Department of Obstetrics and Gynecology,
Trubetskaya str., 8, p. 1, Moscow, 119991
A. G. Solopova
Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation
Russian Federation
MD, Professor of Department of Obstetrics and Gynecology,
Trubetskaya str., 8, p. 1, Moscow, 119991
S. N. Gurov
Cancer clinical dispensary №1 Department of Health of Moscow
Russian Federation
Russian Federation
PhD, Head of the department of chemotherapy,
ul. Baumanskaya, 17/1, Moscow, 105005
A. D. Makatsariya
Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation
Russian Federation
MD, corresponding member of the Russian Academy of Sciences, Professor, Head of the Department of Obstetrics and Gynecology, Faculty of Medical and Preventive,
ul. Trubetskaya, 8, str. 2, Moskva, 119048
References
1. Aksel' E.M. Onkoginekologija. 2012; 1: 18-23.
2. Kaprin A.D., Starinskij V.V., Petrova G.V. Malignancies in Russia in 2013 (morbidity and mortality) [Zlokachestvennye novoobrazovanija v Rossii v 2013 godu (zabolevaemost' i smertnost') (in russian)]. Moscow. 2015; 250 s.
3. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q. et al. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. N Engl J Med. 2006; 354: 34-43.
4. Axtell A.E., Lee M.H., Bristow R.E., Dowdy S.C. Multi-Institutional Reciprocal Validation Study of Computed Tomography Predictors of Suboptimal Primary Cytoreduction in Patients With Advanced Ovarian Cancer. J ClinOncol. 2007; 25: 384-389.
5. Bristow R.E., Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis. Gynecologic Oncology. 2006; 103: 1070-1076.
6. Brockbank E.C., Ind T.E.J., Barton D.P.J. et al. Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. Int J Gynecol Cancer. 2004; 14: 42Y50.
7. Chi D.S., Musa F., Dao F., Zivanovic O., et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). GynecolOncol. 2012 Jan; 124 (1): 10-4.
8. Chudecka-Głaz A.M., Cymbaluk-Płoska A.A., Menkiszak J.L., Sompolska-Rzechuła A.M.
9. et al. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulkingsurgery, response to chemotherapy in ovarian cancer. Journal of Ovarian Research. 2014; 7: 62.
10. Colombo P.E., Labaki M., Fabbro M., Bertrand M. et al. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer. Gynecologic Oncology. 2014; 135: 223-230.
11. da CostaMiranda V., de Souza Fede A.B., Dos Anjos C.H., da Silva J.R. et al. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: safety and effectiveness. Gynecol Oncol. 2014; 132: 287-91.
12. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal Of Cancer. 2009; 45: 228-247.
13. Espada M., Garcia-Flores J.R., Jimenez M., Alvarez-Moreno E. Diffusion-weighted magnetic resonance imaging evaluation of intra-abdominal sites of implants to predict likelihood of suboptimal cytoreductive surgery in patients with ovarian carcinoma. EurRadiol. 2013; 23: 2636-2642.
14. Fagö-Olsen C.L., Ottesen B., Kehlet H.,Antonsen S.L. et al. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study. Gynecologic Oncology. 2014; 132: 292-298.
15. Forstner R., Sala E., Kinkel K., Spencer J.A. ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol. 2010; 20: 2773-2780.
16. Forstner R., Meissnitzer M.W., Schlattau A., Spencer J.A. MRI in ovarian cancer. Imaging Med. 2012; 4 (1): 59-75.
17. Gómez-Hidalgo N.R., Martinez-Cannon B.A., Nick A.M , Lu K.H. Predictors of optimal cytoreduction in patients with newly diagnosed 3 advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol. 2015; 137 (3): 553-8.
18. Griffin N., Grant L.A., Freeman S.J., JimenezLinan M. et al. Image-guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique? Eur Radiol. 2009; 19: 230-235.
19. Höhn A.K., Einenkel J., Wittekind C., Horn L.-C. Neue FIGO-Klassifikation des Ovarial-, Tuben und primären. Peritoneal karzinoms Pathologe. 2014; 35 (4): 322-6.
20. Ibeanu A.O., Bristow R.E. Predicting the Outcome of Cytoreductive Surgery for Advanced Ovarian Cancer. A Review. Int J Gynecol Cancer. 2010; 20: 1-11.
21. Iorio E.,Mezzanzanica D., Alberti P., Spadaro F. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005 Oct 15; 65 (20): 9369-76.
22. Iyer V.R., Lee S.I. MRI, CT, and PET/CT for Ovarian Cancer Detection and adnexal Lesion Characterization. American Journal of Roentgenology. 2010; 194 (2): 311-21.
23. Jung D.C., Kang S., Kim M.J., Park S.Y. et al. Multidetector CT predictors of incomplete resection in primary cytoreduction of patients with advanced ovarian cancer. Eur Radiol. 2010; 20: 100-107.
24. Kehoe S., Hook J., Nankivell M., Jayson G.C. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. The Lancet. 2015; 386: 249-257.
25. Kyriazi S., Kaye Stan B., Nandita M. de Souza Imaging ovarian cancer and peritoneal metastases-current and emerging techniques. Nature reviews. 2010 Jul; 7 (7): 381-93.
26. Ledermann J.A., Raja F.A. et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2013. Ann Oncol. 2013; 24 (6): vi24-vi32.
27. Mitchell D.G., Javitt M.C., Glanc P., Bennet G.L. et al. ACR Appropriateness Criteria: Staging and Follow-up of Ovarian Cancer. J Am Coll Radiol. 2013; 10: 822-827.
28. Morgan R.J., Armstrong D.K., Alvarez R.D, Bakkum-Gamez J.N. et al NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2. 2015.
29. Morrison J., Haldar K., Kehoe S., Lawrie T. A Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer (Review). The Cochrane Collaboration. Published by JohnWiley& Sons, Ltd. 2012.
30. Muñoz-Casares F.C., Rufián S., Arjona-Sánchez Á., Rubio M.J. Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study. Cancer Chemother Pharmacol. 2011 Jul; 68 (1): 267-74.
31. Nougaret S., Addle H.C., Colombo P.E., Fujii S. Ovarian Carcinomatosis: How the Radiologist Can Help Plan the Surgical Approach Radio Graphics. 2012; 32: 1775-1800.
32. Rustin G.J.S., Vergote I., Eisenhauer E., Pujade-Lauraine E. et al. Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011; 21: 419- 423.
33. Rutten M.J., Leeflang M.M.G., Kenter G.G., Mol B.W.J., Buist M. Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer. Cochrane Database of Systematic Reviews. 2014; Issue 2. Art. No.: CD009786.
34. Sala E., Kataoka M.Y., Priest A.N., Gill A.B., et al Advanced Ovarian Cancer: Multiparametric MR Imaging Demonstrates Response- and Metastasis-specific Effects. Radiology. 2012; 263 (1): 149-159.
35. Seward S.M., Winer I. Primary Debulkingsurgert and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Cancer Metastasis Rev. 2015.
36. Stoeckle E., Boubli B., Floquet A., Brouste V. et al. Optimal timing of interval debulking surgery in advanced ovarian cancer: yet to be defined? Eur J Obstet Gynecol Reprod Biol. 2011; 159: 407-12.
37. Thabet A., Somarouthu B., Oliva E., Gervais D.A. et al. Image-Guided Ovarian Mass Biopsy: Efficacy and Safety. J Vasc Interv Radiol. 2014; 25: 1922-1927.
38. Thomassin-Naggara I., Balvay D., Aubert E., Daraï E. Quantitative dynamic contrastenhanced MR imaging analysis of complex adnexal masses: a preliminary study. Eur Radiol. 2012; 22: 738-745.
39. Vergote I., Tropé C.G., Amant F. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363: 943-953.
40. Vorgias G., Iavazzo C., Savvopoulos P. et al. Can the preoperative CA-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study. GynecolOncol. 2009; 112: 11Y15.
41. Yang Z., Luo Z., Zhao B., Zhang W. et al. Diagnosis and preoperative predictive value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancer. Oncology Letters. 2013; 6: 28-34.
Review
For citations:
Solopova A.E., Chashchin A.A., Solopova A.G., Gurov S.N., Makatsariya A.D. NEOADJUVANT CHEMOTHERAPY FOR EPITHELIAL OVARIAN CANCER. MODERN METHODS AND PATIENTS SELECTION CRITERIA. Obstetrics, Gynecology and Reproduction. 2016;10(2):44-54. (In Russ.) https://doi.org/10.17749/2313-7347.2016.10.2.044-054
Views: 634
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
